

Sweden patient group funding

Posithiva gruppen

Posithiva Gruppen (The Posithive Group, PG) is a nationwide non-profit, politically and religiously independent companion and support organization. Their purpose is to educational people living with HIV, give support and offer psychosocial activities and create a forum for exchange of experience. They also work for the rights for people living with HIV and to increase knowledge about HIV in the Swedish society, including working against stigma and prejudice.

We have supported this group since 2007.

During 2021:

- GSK provided a funding of 30.000 SEK, for the project: "World Aids Day 2021". Memory ceremony in Maria Magdalena church on World Aids Day Dec 1, 2021 and advertising in paper QX.

Our support represented 0,56 % of their overall income.
Sweden patient group funding

Hiv-Sverige

Hiv-Sverige is an umbrella organisation. They work for the rights for people living with HIV (PLHIV) in society. Hiv-Sverige goals are:

- Work against discrimination of PLHIV.
- Try to abolish negative attitudes against PLHIV.
- Work for equal rights in society for PLHIV.
- Improve conditions for PLHIV.
- Promote PLHIV’s position in society.
- Facilitate for PLHIV to return to work life.

We have supported this group since 2009.

During 2021:

- GSK provided a funding of 60,000 SEK for the project: “Candlelight Memorial Day 2021”. The purpose of this day is to make visible the need for more interventions and innovations within HIV. The target groups for the day are people working with HIV, people living with HIV, their closest and politicians.

Our support represented 2,4 % of their overall income.
Swedish patient group funding

Nätverk mot Gynekologisk cancer

Nätverk för Gynekologisk cancer is a network of patients, relatives and more involved who spread knowledge, push for improvements and create debate about gynecological cancers.

- They support women affected by gynecological cancer by making higher demands on today's health care.
- They work to ensure that the health care is more active with prevention and that all affected women should have access to optimal care, treatment and rehabilitation without any delay.
- They also work for more research.

We have supported this group since 2020.

During 2021:

- GSK provided a funding of 25,000 SEK for the project: “Gyncancerdag 2021”.
  
  The project’s objective(s) are Gyncancerdagarna and its duration is 20210417.
  The project will consist of one online meeting.
  The target audience is intended to be patients, HCP.
  The roles and responsibilities of GSK and Patient Organisation are that the Patient organisation are organizing the evening meetings and GSK is funding it as one of four companies together.

Our support represented 3.57% of their overall income.
Sweden patient group funding

1,6 Miljonerklubben

The 1.6 million club is a non-profit women's health organization founded in 1998. We work for women's health and for the gender aspect to become a mandatory part of medical research and medical education.

We have supported this group since 2021.

During 2021:

- GSK provided a funding of 36,000 SEK for the project: “Bältros Webinar september 2021”.

  Webinar with 4 panel seats for experts and patient/person with experience of the disease shingles on 9 September 2021.

  GSK has chosen to sponsor this activity because we are active in the Bältros disease area. GSK works to raise knowledge about the disease shingles to both healthcare and the general public. GSK believes that this webinar will be a valuable source and opportunity for a large group in the public to learn more about the disease shingles and that it is possible to prevent it.

  Our support represented 2.2% of their overall income.
Blodcancerförbundet

Blodcancerförbundet exists for those affected by blood cancer or other serious blood disease, relatives and staff in hematology. The association is a non-profit nationwide patient organization that is a member of the interest-political umbrella organizations Funktionsrätt Sverige och Nätverket mot cancer. We see ourselves as the "voice of those affected by blood cancer" and work actively, committedly and long-term to contribute to a better everyday life for the country's blood and blood cancer victims.

We have supported this group since 2021.

During 2021:

- GSK provided a funding of 103 531 SEK for the project: “Dagens forskning, morgondagens behandling”.

Blodcancerförbundet, GSK and several other companies (AbbVie, Amgen, BMS, Jansen, Pfizer, Roche, Sanofi) have identified the problems surrounding patients’ access to new effective blood cancer treatments, blood cancer patients' access to clinical trials and the lack of patient influence at system level in HTA issues. Together, the parties wish to carry out a campaign in the autumn of 2021 and the spring of 2022 under the name "Dagens Forskning - Morgondagens Behandling" to address these problems and show possible solutions.

The campaign consists of several different parts such as a survey of regional and national politicians regarding blood cancer, production of a fact report on blood cancer, creation of films aimed at politicians, decision makers and the general public to increase knowledge about blood cancer, show the importance of clinical trials and why access to new drugs is important. We will also arrange dialogue meetings and roundtable discussions with politicians both nationally and regionally, as well as a seminar under the Folkhälsodalen.

Planning meetings will be held continuously between the Blodcancerförbundet, the companies, and the external supplier.

- GSK provided a funding of 3600 SEK for the project: “The project’s objective is: to give people working at GSK insight about blood cancer diseases.”.

The project’s objective is: to give people working at GSK insight about blood cancer diseases. GSK is active in the field of multiple myeloma and this talk is in line with GSKs swim lane “Trust” which will give people working at GSK insight of the importance working with hematology. Duration will be 1-hour virtual meeting, the 11th of March 2021 at a “Lunch and Learn meeting” for GSK Pharma Solna.

The project will consist of a presentation with information about what
Sweden patient group funding

“Blodcancerförbundet” is working on as well as the patient perspective of those who unfortunately are affected, including a section with question and answer and discussion.

The target audience is intended to be people working at GlaxoSmithKline AB.

Our support represented 1,34 % of their overall income.